

30 September 2009

TENDER RESULTS

The PHARMAC Board (or Chief Executive under delegated authority) has resolved to accept and decline tenders for Sole Subsidised Supply and Hospital Supply Status for some of the products listed in the Invitation to Tender dated 21 December 2007 and Invitation to Tender dated 23 December 2008.

Some of the pharmaceuticals that will be delisted when the period of sole supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts until such time as the pharmaceuticals are delisted and PHARMAC will continue to subsidise their pharmaceuticals accordingly.

Product Notification Forms

Please note that for all changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H) suppliers are required to notify PHARMAC and the Guild by 4pm **12th October 2009**. More information and product notification forms can be downloaded from our website – www.pharmac.govt.nz/schedule.asp.

2007/08 Tender

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status

The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 21 December 2007.

The decisions were as follows:

Chemical Name	Line Item
Clindamycin	Cap hydrochloride 150 mg
Dihydrocodeine Tartrate	Tab long-acting 60 mg
Docusate Sodium with Sennosides	Tab 50 mg with total sennosides 8 mg
Ethinylloestradiol with Levonorgestrel	Tab ethinylloestradiol 30 mcg with levonorgestrel 50 mcg (6) and ethinylloestradiol 40 mcg with levonorgestrel 75 mcg (5), and ethinylloestradiol 30 mcg with levonorgestrel 125 mcg (10) and 7 inert tab
Gelatin Plasma Replacer	Inf 4% 500 ml bag
Ibuprofen	Tab 400 mg
Ibuprofen	Tab 600 mg
Ibuprofen	Tab long-acting 800 mg
Iron Sucrose*	Inj 20 mg per ml
Minocycline Hydrochloride	Cap 100 mg
Minocycline Hydrochloride	Tab 50 mg
Phenobarbitone Sodium	Inj 200 mg per ml, 1 ml
Tranexamic Acid	Tab 500 mg

* This tender decline was for the community market only.

2008/09 Tender

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where at least one other brand is listed – listing for tender winning brand at the tender subsidy will occur on **1 October 2009**, reference pricing of non-tender winning brand will occur on **1 December 2009** and Sole Subsidised Supply commences on **1 March 2010**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy	New tender subsidy	Sole supply brand (Supplier)	Brands affected by reference pricing and delisting
Diclofenac sodium	Tab EC 25 mg; 50 tablets, blister	\$3.51 (for 100 tablets)	\$1.63	Diclohexal (Sandoz)	Apo-Diclo (Apotex)
Diclofenac sodium	Tab EC 50 mg; 50 tablets, blister	\$25.88 (for 500 tablets)	\$2.13	Diclohexal (Sandoz)	Apo-Diclo (Apotex)

2. Tenders awarded to pharmaceuticals where at least one other brand is listed – listing for tender winning brand at the tender subsidy will occur on **1 November 2009**, reference pricing of non-tender winning brand will occur on **1 January 2010** and Sole Subsidised Supply commences on **1 April 2010**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy	New tender subsidy	Sole supply brand (Supplier)	Brands affected by reference pricing and delisting
Amoxicillin clavulanate	Grans for oral liq 125 mg with potassium clavulanate 31.25 mg per 5 ml; 100 ml, bottle	\$2.75	\$2.20	Curam (Sandoz)	Augmentin (GSK)
Amoxicillin clavulanate	Grans for oral liq 250 mg with potassium clavulanate 62.5 mg per 5 ml; 100 ml, bottle	\$4.75	\$3.85	Curam (Sandoz)	Augmentin (GSK)
Cyproterone acetate with ethinyloestradiol	Tab 2 mg with ethinyloestradiol 35 µg and 7 inert tabs; 84 tablets; blister	\$6.30	\$4.91	Ginet 84 (Rex)	Estelle 35 ED (Douglas)
Metformin hydrochloride	Tab immediate-release 500 mg; 500 tablets, bottle	\$9.75	\$8.09	Apotex (Apotex)	Arrow-Metformin (Arrow)
Metformin hydrochloride	Tab immediate-release 850 mg; 250 tablets, bottle	\$8.00	\$6.67	Apotex (Apotex)	Arrow-Metformin (Arrow)
Mometasone furoate	Crm 0.1%; 15 g OP, tube	\$3.96	\$2.38	m-Mometasone (Multichem)	Elocon (Schering-Plough)
Mometasone furoate	Crm 0.1%; 45 g OP, tube	\$10.82	\$4.55	m-Mometasone (Multichem)	Elocon (Schering-Plough)
Mometasone furoate	Oint 0.1%; 15 g OP, tube	\$3.96	\$2.38	m-Mometasone (Multichem)	Elocon (Schering-Plough)
Mometasone furoate	Oint 0.1%; 45 g OP, tube	\$10.82	\$4.55	m-Mometasone (Multichem)	Elocon (Schering-Plough)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

3. Tenders awarded to listed pharmaceuticals where only the current brand is listed – price changes (where applicable) for hospital tender winning brands of the pharmaceuticals will occur in Section H of the Pharmaceutical Schedule on **1 November 2009**; DV Limits and DV Pharmaceuticals will apply from **1 January 2010**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
Idarubicin hydrochloride	Cap 5 mg; 1 capsule, blister	Zavedos (Pfizer)	\$115.00	1%	(B)
Idarubicin hydrochloride	Cap 10 mg, 1 capsule, blister	Zavedos (Pfizer)	\$144.50	1%	(B)
Idarubicin hydrochloride	Inj 5 mg, 1 injection, vial	Zavedos (Pfizer)	\$170.00	1%	(B)
Idarubicin hydrochloride	Inj 10 mg, 1 injection, vial	Zavedos (Pfizer)	\$340.00	1%	(B)

4. Tenders awarded to listed pharmaceuticals where an alternative brand is already listed – listing for hospital tender winning brands of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on **1 November 2009**; DV Limits and DV pharmaceuticals will apply from **1 January 2010**; de-listing of other brands in Section H will occur on **1 January 2010**.

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
Amoxicillin clavulanate	Grans for oral liq 125 mg with potassium clavulanate 31.25 mg per 5 ml; 100 ml, bottle	Curam (Sandoz)	\$2.20	1%	Alpha-Amoxyclav (Apotex) Augmentin (GSK) Synermox (Douglas)
Amoxicillin clavulanate	Grans for oral liq 250 mg with potassium clavulanate 62.5 mg per 5 ml; 100 ml, bottle	Curam (Sandoz)	\$3.85	1%	Alpha-Amoxyclav (Apotex) Augmentin (GSK) Synermox (Douglas)
Amoxicillin clavulanate	Inj 600 mg; 10 injections, vial	Curam (Sandoz)	\$12.67	1%	Augmentin (GSK) Synermox (Douglas)
Amoxicillin clavulanate	Inj 1.2 g; 10 injections, vial	Curam (Sandoz)	\$16.50	1%	Augmentin (GSK) Synermox (Douglas)
Metformin hydrochloride	Tab immediate-release 500 mg; 500 tablets, bottle	Apotex (Apotex)	\$8.09	1%	3M Metformin (Douglas) Arrow-Metformin (Arrow) Glucomet (Douglas) Metomin (Mylan)
Metformin hydrochloride	Tab immediate-release 850 mg; 250 tablets, bottle	Apotex (Apotex)	\$6.67	1%	3M Metformin (Douglas) Arrow-Metformin (Arrow) Glucomet (Douglas) Metomin (Mylan)
Mometasone furoate	Crn 0.1%; 15 g, tube	m-Mometasone (Multichem)	\$2.38	1%	Elocon (Schering-Plough)
Mometasone furoate	Crn 0.1%; 45 g, tube	m-Mometasone (Multichem)	\$4.55	1%	Elocon (Schering-Plough)
Mometasone furoate	Oint 0.1%; 15 g, tube	m-Mometasone (Multichem)	\$2.38	1%	Elocon (Schering-Plough)
Mometasone furoate	Oint 0.1%; 45 g, tube	m-Mometasone (Multichem)	\$4.55	1%	Elocon (Schering-Plough)
Oxaliplatin*	Inj 50 mg; 1 injection, vial	Oxaliplatin Ebewe (InterPharma)	\$65.00	1%	Hospira (Hospira)

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
					Eloxatin (Sanofi-Aventis) Oxaliplatin Dakota (Sanofi-Aventis) Oxaliplatin Winthrop (Sanofi-Aventis)
Oxaliplatin*	inj 100 mg; 1 injection, vial	Oxaliplatin Ebewe (InterPharma)	\$130.00	1%	Hospira (Hospira) Eloxatin (Sanofi-Aventis) Oxaliplatin Dakota (Sanofi-Aventis) Oxaliplatin Winthrop (Sanofi-Aventis)

*Please note Oxaliplatin Ebewe will also be listed in Section B of the Pharmaceutical Schedule for PCT and the ECP price for oxaliplatin will be amended accordingly, from 1 January 2010.

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status

The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 23 December 2008.

The decisions were as follows:

Chemical Name	Line Item
Dantrolene Sodium	Inj 1 mg per ml, 20 ml
Metaraminol Tartrate	Inj 10 mg per ml, 1 ml
Nicotinic Acid	Tab 500 mg
Rocuronium	Inj 10 mg per ml, 10 ml

For the remaining products on the Invitation to Tender dated 21 December 2007 and the Invitation to Tender dated 23 December 2008 where no announcement has been made, either a decision is still pending, or is provisional and subject to the product gaining market approval and having sufficient stock.

We will keep you informed regarding any changes for the remaining tender products as further decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.